Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Eastern Cooperative Oncology Group
NRG Oncology
Eurofarma Laboratorios S.A.
UNICANCER
Inovio Pharmaceuticals
Oncolytics Biotech
Gustave Roussy, Cancer Campus, Grand Paris
Vical